FoundationOne CDx comprehensively examines the tumour genome, assessing the four main classes of genomic alteration in 324 known cancer-relevant genes, while also reporting TMB and MSI, which can help inform the use of immunotherapies.3,4
FoundationOne CDx is based on our analytically and clinically validated, FDA-approved comprehensive platform.1,5 You can be confident in the insights generated by FoundationOne CDx thanks to the review and approval of the workflow by the FDA, including analytical and clinical validation, and bioinformatics.3
Review and approval of the FoundationOne CDx platform workflow by the FDA
What is the difference between analytical and clinical validation?
Supports clinical decision-making
A clear, in-depth report provides insights on your patient’s genomic profile as well as associated targeted therapies, immunotherapies and relevant clinical trials. The report also highlights important disease-relevant genes with no reportable alterations identified and genomic alterations associated with potential resistance to therapy to help rule out potentially ineffective treatment.6